The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment

作     者：Lambertus P.van den Heuvel Nicole C.A.J.van de Kar Caroline Duineveld Andrei Sarlea Thea J.A.M.van der Velden Wilhelmus T.B.Liebrand Sanne van Kraaij Camilla Schjalm Romy Bouwmeester Jack F.M.Wetzels Tom E.Mollnes Elena B.Volokhina Lambertus P.van den Heuvel;Nicole C.A.J.van de Kar;Caroline Duineveld;Andrei Sarlea;Thea J.A.M.van der Velden;Wilhelmus T.B.Liebrand;Sanne van Kraaij;Camilla Schjalm;Romy Bouwmeester;Jack F.M.Wetzels;Tom E.Mollnes;Elena B.Volokhina

作者机构：Department of Pediatric Nephrology Amalia Children’s HospitalRadboud University Medical CenterRadboud Institute for Molecular Life SciencesNijmegenThe Netherlands Department of Laboratory MedicineRadboud University Medical CenterRadboud Institute for Molecular Life SciencesNijmegenThe Netherlands Department of PediatricsUniversity Hospitals LeuvenLeuvenBelgium Department of NephrologyRadboud University Medical CenterRadboud Institute for Health SciencesNijmegenThe Netherlands Department of ImmunologyOslo University Hospital and University of OsloOsloNorway Research LaboratoryNordland HospitalBodøand K.G.Jebsen TRECUniversity of TromsøTromsøNorway Center of Molecular Inflammation ResearchNorwegian University of Science and TechnologyTrondheimNorway 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2020年第17卷第6期

页      面：653-655页

核心收录：

学科分类：1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基　　金：supported by grants from ZonMw,“Goed Gebruik Geneesmiddelen”(project number 836031008) the Zorgverzekeraars Nederland and Dutch Kidney Foundation(13OCA27 COMBAT Consortium) 

主　　题：hemolytic rabbit gravis 

摘      要：Dear Editors,Eculizumab is a therapeutic complement C5 inhibitor approved for the treatment of atypical hemolytic uremic syndrome(aHUS),paroxysmal nocturnal proteinuria(PNH),generalized myasthenia gravis and neuromyelitis optica spectrum *** dosing of eculizumab is important to ensure complete complement *** activity is often monitored by measuring either formation of the C5 activation product C5b-9 in vitro using an ELISA,independent of red blood cells,or by hemolytic assays measuring hemoglobin release from *** approaches allow analysis of complement activation via the classical(CP)and alternative(AP)pathways.